Paper39201418
Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches.
Ferdous SE and 1 other. Int J Mol Sci, 2024. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Papers, record 39201418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39201418
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Humans | |
| Animals | |
| Metabolic Syndrome | |
| Insulin Resistance | |
| Fatty Liver | |
| Non-alcoholic Fatty Liver Disease |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AA015951 | NIAAA NIH HHS | United States | R01AA015951 | PubMed and NIH | NIH RePORTER |
| 1R01AA015951-17A1 | NIH HHS | United States | R01AA015951 | PubMed and NIH | NIH RePORTER |
| R56 DK044442 | NIDDK NIH HHS | United States | R01DK044442 | PubMed and NIH | NIH RePORTER |
| R01 DK044442 | NIDDK NIH HHS | United States | R01DK044442 | PubMed and NIH | NIH RePORTER |
| 1R01DK044442-26A1 | NIH HHS | United States | R01DK044442 | PubMed and NIH | NIH RePORTER |
References95
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35325622 | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35325622 | PubMed |
| 2 | 37230214 | Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD. | Metabolism | 2023 | https://conductscience.org/library/papers/37230214 | PubMed |
| 3 | 32019723 | A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus. | J Diabetes Complications | 2020 | https://conductscience.org/library/papers/32019723 | PubMed |
| 4 | 26399788 | GPR119: a promising target for nonalcoholic fatty liver disease. | FASEB J | 2016 | https://conductscience.org/library/papers/26399788 | PubMed |
| 5 | 38521116 | The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. | Clin Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38521116 | PubMed |
| 6 | 25512491 | Identification of S-nitroso-CoA reductases that regulate protein S-nitrosylation. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25512491 | PubMed |
| 7 | 23017715 | Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism. | Vitam Horm | 2012 | https://conductscience.org/library/papers/23017715 | PubMed |
| 8 | 30158026 | Recent insights into the role of ChREBP in intestinal fructose absorption and metabolism. | BMB Rep | 2018 | https://conductscience.org/library/papers/30158026 | PubMed |
| 9 | 37088458 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/37088458 | PubMed |
| 10 | 30605011 | Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. | Am J Physiol Gastrointest Liver Physiol | 2019 | https://conductscience.org/library/papers/30605011 | PubMed |
| 11 | 31697972 | Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. | J Hepatol | 2020 | https://conductscience.org/library/papers/31697972 | PubMed |
| 12 | 29358469 | Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. | Diabetes Care | 2018 | https://conductscience.org/library/papers/29358469 | PubMed |
| 13 | 34956080 | Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34956080 | PubMed |
| 14 | 33724511 | Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. | Hepatology | 2021 | https://conductscience.org/library/papers/33724511 | PubMed |
| 15 | 27639537 | Clinical relevance of the bile acid receptor TGR5 in metabolism. | Lancet Diabetes Endocrinol | 2017 | https://conductscience.org/library/papers/27639537 | PubMed |
| 16 | 36866389 | Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. | JHEP Rep | 2023 | https://conductscience.org/library/papers/36866389 | PubMed |
| 17 | 16410358 | Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16410358 | PubMed |
| 18 | 35581956 | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | Hepatol Commun | 2022 | https://conductscience.org/library/papers/35581956 | PubMed |
| 19 | 22431203 | The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. | J Pharmacol Exp Ther | 2012 | https://conductscience.org/library/papers/22431203 | PubMed |
| 20 | 24583089 | Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators. | Pharmacol Ther | 2014 | https://conductscience.org/library/papers/24583089 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42613422 | Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42613422 | PubMed |
| 42510904 | Centella Asiatica Alleviates Type 2 Diabetes-Related Hepatic Glycolipid Disorders via Regulating UPP1-Mediated Pyrimidine Metabolism. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42510904 | PubMed |
| 42505401 | Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. | Cells | 2026 | https://conductscience.org/library/papers/42505401 | PubMed |
| 42461275 | Imaging of MASLD: clinical standards and novel methods. | Diabetologia | 2026 | https://conductscience.org/library/papers/42461275 | PubMed |
| 42416572 | Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42416572 | PubMed |
| 42305303 | Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review. | Arch Med Sci | 2026 | https://conductscience.org/library/papers/42305303 | PubMed |
| 42278284 | Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278284 | PubMed |
| 42265657 | Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease. | BMC Endocr Disord | 2026 | https://conductscience.org/library/papers/42265657 | PubMed |
| 42242850 | Association between uric acid to high-density lipoprotein cholesterol ratio (UHR) and osteoporosis in type 2 diabetes with MASLD. | Asia Pac J Clin Nutr | 2026 | https://conductscience.org/library/papers/42242850 | PubMed |
| 42072294 | Type 2 Diabetes Mellitus as a Multisystem Disease: From Insulin Resistance to Organ Crosstalk-A Narrative Review. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072294 | PubMed |
| 42005636 | Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42005636 | PubMed |
| 41928145 | Demographic profiles and disparities in all liver diseases and diabetes mellitus patients - related mortality among older adults (≥ 65) in the United States, 1999 to 2020. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/41928145 | PubMed |
| 41835376 | Gentiopicroside alleviates type 2 diabetes mellitus by attenuating oxidative stress and reshaping gut microbiota in high-fat diet and streptozotocin-induced mice. | Front Nutr | 2026 | https://conductscience.org/library/papers/41835376 | PubMed |
| 41767367 | A pilot study on a combined non-invasive screening test for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41767367 | PubMed |
| 41749862 | Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749862 | PubMed |
| 41635536 | Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41635536 | PubMed |
| 41507142 | Multicompartment hydrogel microcapsules for creating spatially patterned cell co-cultures. | Microsyst Nanoeng | 2026 | https://conductscience.org/library/papers/41507142 | PubMed |
| 41441969 | Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study. | Diabetes Ther | 2026 | https://conductscience.org/library/papers/41441969 | PubMed |
| 41398609 | Association between De Ritis ratio and mortality in individuals with diabetes or prediabetes: evidence from NHANES (1999-2018). | Eur J Med Res | 2025 | https://conductscience.org/library/papers/41398609 | PubMed |
| 41334445 | Microbiome-mediated crosstalk between T2DM and MASLD: a translational review focused on function. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41334445 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39201418
GET https://conductscience.org/api/papers/v1/39201418/references?page=2